MarketPeel
Insider Trading Intelligence
Pricing
…
SB

Scott N. Boyle

CCCC
CHIEF BUSINESS OFFICER · C4 THERAPEUTICS, INC. · CIK 0001913897
FILING MIX · LIFETIME47%/53%
BUYS
16
SELLS
18
TOTAL VALUE
$75.1K
COMPANIES
1
ACTIVE SINCE
May 2022
HOLDINGS NOW
306,070
AVG SELL PX
$3.62
TRADE KIND
SHOWING 34 / 34
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 2 pending
Forward-return performance of every backtestable P/S trade by Scott N. Boyle, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+100.00%-5.70%-2.21%-3.49%-3.49%—
14d2+100.00%-17.32%-4.10%-13.22%-13.22%—
30d2+100.00%-30.27%-7.25%-23.02%-23.02%—
60d2+100.00%-60.25%-12.61%-47.64%-47.64%—
90d2+100.00%-52.38%-2.65%-49.73%-49.73%—
180d2+100.00%-15.22%+5.80%-21.02%-21.02%—
1y2+100.00%-38.13%+12.36%-50.49%-50.49%—
2y2(2 pending)——————
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CCCC · 306,070 shares · as of Feb 14, 2026
076,951153,903230,854307,8052023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 16 buys / 18 sellsCOVERAGE · 16 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CCCC
C4 THERAPEUTICS, INC.
SALE
Chief Business Officer
7,269$1.89$13.7K298,801Feb 14, 2026Feb 18, 2026 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
20,950——306,070Feb 14, 2026Feb 18, 2026 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
Chief Business Officer
1,735$1.89$3.3K306,070Feb 13, 2026Feb 18, 2026 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
200,000——307,805Feb 13, 2026Feb 18, 2026 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
5,000——307,805Feb 13, 2026Feb 18, 2026 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
669$3.15$2.1K107,805Feb 18, 2025Feb 18, 2025 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
84,700——84,700Feb 14, 2025Feb 18, 2025 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
Chief Business Officer
2,368$3.18$7.5K108,474Feb 14, 2025Feb 18, 2025 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
56,500——111,332Feb 14, 2025Feb 18, 2025 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
490$3.15$1.5K110,842Feb 14, 2025Feb 18, 2025 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
Chief Business Officer
1,735$3.20$5.6K54,832Feb 13, 2025Feb 18, 2025 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
3,750——57,669Nov 7, 2024Nov 12, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
Chief Business Officer
1,102$6.04$6.7K56,567Nov 7, 2024Nov 12, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
Chief Business Officer
3,750——10,500Nov 7, 2024Nov 12, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
2,250——54,580Sep 16, 2024Sep 17, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
Chief Business Officer
2,250——14,250Sep 16, 2024Sep 17, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
Chief Business Officer
661$6.36$4.2K53,919Sep 16, 2024Sep 17, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
Chief Business Officer
115,000——0Mar 7, 2024Mar 8, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
115,000——115,000Mar 7, 2024Mar 8, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
122,800——122,800Feb 14, 2024Feb 15, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
27,300——52,330Feb 14, 2024Feb 15, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
Chief Business Officer
1,735$6.53$11.3K25,030Feb 13, 2024Feb 15, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
120,000——120,000Sep 18, 2023Sep 19, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
Chief Business Officer
661$2.93$1.9K26,765Aug 30, 2023Aug 31, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
Chief Business Officer
2,250——16,500Aug 30, 2023Aug 31, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
2,250——27,426Aug 30, 2023Aug 31, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,000——25,176Feb 13, 2023Feb 15, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
90,000——90,000Feb 13, 2023Feb 15, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
Chief Business Officer
1,222$7.78$9.5K5,176Jan 30, 2023Feb 1, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
3,750——6,398Jan 30, 2023Feb 1, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
Chief Business Officer
3,750——18,750Jan 30, 2023Feb 1, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
Chief Business Officer
1,102$7.01$7.7K2,648May 26, 2022Jun 14, 2022 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
3,750——3,750May 25, 2022May 27, 2022 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
Chief Business Officer
3,750——22,500May 25, 2022May 27, 2022 ↗View →
Other insiders · CCCC
Loading peer insiders…
About this filer
CIK 0001913897
ROLE
Chief Business Officer
PRIMARY
CCCC
COMPANIES
1
ACTIVE SINCE
May 2022
MARKETPEEL · /INSIDER/0001913897DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback